USA flag logo/image

An Official Website of the United States Government

Universal Influenza DNA vaccine with Novel Toll-Like Receptor Adjuvants

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88779
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI079930
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PROFECTUS BIOSCIENCES, INC.
6411 Beckley St BALTIMORE, MD 21224-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Universal Influenza DNA vaccine with Novel Toll-Like Receptor Adjuvants
Agency: HHS
Contract: 1R43AI079930-01
Award Amount: $256,171.00
 

Abstract:

DESCRIPTION (provided by applicant): The enhanced safety, stability, and accelerated product development generally provided by DNA vaccination make it an appealing approach to develop a universal influenza vaccine. Unfortunately, successful DNA vaccinati on of primates requires multiple inoculations with undesirably large doses of plasmid. Genetically encoded adjuvants could provide the dose-sparing effect necessary to realize a practical DNA-based universal vaccine for influenza. We intend to exploit do minant-positive versions of Toll-like receptors (DP-TLRs) to provide the immune activation necessary to initiate such a protective immune response from DNA vaccination. Our vaccine targets for these proof-of-concept studies will be matrix 2 (M2) and nucl eoprotein (NP), two antigens that exhibit a high degree of homology among strains of influenza and have been widely considered for such universal vaccines. We will pursue our objectives through the following specific aims: (1) construct DP-versions of TL R2, TLR4 and TLR9 and evaluate their capacity to activate NF-?B in human and mouse in vitro cell based assays; (2) evaluate the adjuvanticity of DP-TLRs co-formulated with plasmids expressing influenza M2 and NP in mice and (3) evaluate the dose-sparing ef fects of the DP- TLRs for the plasmids expressing influenza M2 and NP in murine viral challenge study. The adjuvant constructs that significantly improve immunogenicity or yield significant reductions in the protective dose over GM-CSF or IL-12 will be fur ther evaluated in mice, ferret, and primate studies as components of an advanced influenza DNA vaccine in a Phase II SBIR application. PUBLIC HEALTH RELEVANCE: The objective of this project is to develop novel adjuvants that will support and improve the ef ficacy of a universal influenza DNA vaccine. These adjuvants will be based on dominant-positive toll-like receptors that activate through NF-?B signalling.

Principal Investigator:

Small Business Information at Submission:

PROFECTUS BIOSCIENCES, INC.
TECHCENTER@UMBC 1450 SOUTH ROLLING RD. BALTIMORE, MD 21227

EIN/Tax ID: 102057941
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No